Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZV1
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZV1 is a novel, selective, small-molecule antagonist of the transient receptor potential vanilloid 1 (TRPV1) channel originally developed by AstraZeneca. While initially designed as a therapeutic approach to suppress nociceptive pain, AZV1 has also been investigated for its metabolic effects. In preclinical studies using ob/ob mouse models of obesity and diabetes, oral administration of AZV1 was shown to significantly lower plasma glucose and fructosamine levels and improve insulin sensitivity without affecting body weight, food intake, or lipid levels. This suggests that TRPV1 antagonism via AZV1 may represent a promising therapeutic strategy for the treatment of type 2 diabetes and metabolic syndrome.
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on AZV1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZV1.